Acute myeloid leukemia (AML) is a heterogeneous blood cancer arising from clonal expansion of myeloid precursors in bone marrow, causing marrow failure and circulating blasts. It is also called acute myelogenous leukemia and requires rapid specialist treatment.
MD Anderson researchers developed GT19630, a first-in-class dual-degrader targeting MYC and GSPT1, showing potent preclinical activity in blood cancers including treatment-resistant and TP53-mutated disease. The drug also restored venetoclax sensitivity in resistant AML models.
New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
A CML blast phase prognostic score separates patients into three risk groups with distinct survival. Separate AML studies identified circRNA and NFS1/GSDMD biomarkers; a T-ALL study highlighted markers including CD38, CD99, and TRBC1.
A rare BTK A428D mutation causes resistance to all BTK-targeted therapies, finds a new study. China is reviewing the first CAR-T therapy for gastric cancer, and research reveals why BET inhibitors fail and targets AML's DNMT3A mutation.
Kura Oncology's ziftomenib shows 96% complete response in frontline AML and $5.8M in early commercial sales; updated FIT-001 trial data for kidney cancer to be presented at 2026 summit; analysts see significant upside with an average target of $32.45.
New CAR T-cell data show 100% MRD negativity in high-risk smoldering multiple myeloma, a novel CAR T approach for AML, and a new T-cell pathway, while a case report warns of a rare therapy-related complication.
Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.
The FDA has cleared an IND for Amphista's novel BRD9 degrader AMX-883 for AML, approved Lantheus' new prostate cancer imaging agent Pylarify TruVu, and accepted Biofrontera's sNDA for Ameluz PDT in superficial basal cell carcinoma. These regulatory milestones span hematologic and solid tumor areas, addressing significant unmet medical needs.
Two separate clinical trials have reported advances in cancer care. An oral drug combination of decitabine-cedazuridine and venetoclax showed efficacy in older patients with acute myeloid leukemia, with a 47% complete response rate in a phase 2b trial. A separate randomized controlled trial found that delaying pegfilgrastim administration to 72 hours post-chemotherapy significantly reduced bone pain in women with stage I–III breast cancer.
Moleculin Biotech's Phase 2B/3 MIRACLE trial of Annamycin plus cytarabine in relapsed or refractory acute myeloid leukemia reported a preliminary complete remission rate of approximately 30% and composite remission rate exceeding 40% in the first 45 subjects. The blinded data show a substantial improvement over historical rates with cytarabine alone. The trial is expected to reach its first unblinding milestone in mid-2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07748455 |
HMA-Venetoclax Induction in Newly Diagnosed AML |
NOT_YET_RECRUITING | PHASE2 |
| NCT07702578 |
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation |
RECRUITING | PHASE3 |
| NCT07695571 |
Model-Informed Precision Dosing on Cyclosporine Therapy in Hematopoietic Stem Cell Transplant Recipients |
NOT_YET_RECRUITING | |
| NCT07661095 |
A Study of CRD3874-SI in People With Leukemia |
RECRUITING | PHASE1 |
| NCT07617285 |
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML |
RECRUITING | PHASE1 |
| NCT07587944 |
Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity |
RECRUITING | |
| NCT07539818 |
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML |
NOT_YET_RECRUITING | PHASE3 |
| NCT07516353 |
my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults |
NOT_YET_RECRUITING | NA |
| NCT07508982 |
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML |
RECRUITING | PHASE1/PHASE2 |
| NCT07493538 |
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases |
RECRUITING | PHASE2 |
